KNSA logo

KINIKSA PHARMACEUTICALS INTE

KNSANASDAQ
🏆 #1142 by market capEarnings Feb 22US Equity
$95.26▲ $6.22 (+6.99%)
After hours · at close
🔔
Track KNSA
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 7.0%
7d▲ 19.6%
14d▲ 20.8%
30d▲ 25.2%
ytd▲ 131.3%
1y▲ 140.3%
🏦Market Cap
$7.43B
Small Cap
📈Revenue Growth (YoY)
58.9%
High Growth
📊Gross Margin
89.8%
High
💵FCF Margin
21.7%
Strong
⚖️P/S Ratio
6.8x
Fair
Otter Score
72
Strong

Trading Snapshot

Day Range
$87.67 – $95.27
52-Week Range
$35.20 – $84.06
Volume (shares)
143,879
Avg Volume (shares)
—
Shares Outstanding
78.0M
Next Earnings
2027-02-22

Fundamentals Snapshot

Annual Revenue
$678M
Last Q Revenue
$286M
P/E Ratio
70.9
P/S Ratio
6.8x
EPS (TTM)
$0.98
Dividend Yield
—
Dilution (1yr)
+9.2%
KNSA logo

KINIKSA PHARMACEUTICALS INTE

KNSA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$678M▲ +60.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
54.6%▼ −36.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$77M▼ −269.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$25M▲ +0.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
79.0M▲ +9.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$156M▼ −$18M YoY
StockOtter · stockotter.space

About KINIKSA PHARMACEUTICALS INTE

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Strong
72/100

Analyst Ratings

ⓘ
Consensus
Buy
14 analysts
Strong Buy5
Buy8
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.